Last reviewed · How we verify

Lymphostat B — Competitive Intelligence Brief

Lymphostat B (BELIMUMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: B Lymphocyte Stimulator-specific Inhibitor [EPC]. Area: Oncology.

marketed B Lymphocyte Stimulator-specific Inhibitor [EPC] Tumor necrosis factor ligand superfamily member 13B Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Lymphostat B (BELIMUMAB) — Human Genome Sciences Inc.. Belimumab works by blocking the B Lymphocyte Stimulator, a protein that can contribute to the autoimmune response in Systemic lupus erythematosus.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lymphostat B TARGET BELIMUMAB Human Genome Sciences Inc. marketed B Lymphocyte Stimulator-specific Inhibitor [EPC] Tumor necrosis factor ligand superfamily member 13B 2011-01-01
Benlysta Benlysta GlaxoSmithKline marketed Tumor necrosis factor ligand superfamily member 13B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (B Lymphocyte Stimulator-specific Inhibitor [EPC] class)

  1. Human Genome Sciences Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lymphostat B — Competitive Intelligence Brief. https://druglandscape.com/ci/belimumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: